Gilberto Mossetto currently serves as a Medical Science Liaison specializing in Diabetes and Obesity at Eli Lilly, where he leverages his extensive expertise in endocrinology and pediatrics to drive impactful healthcare solutions. With a Six Sigma Green Belt certification obtained in 2009, Gilberto is adept...
Gilberto Mossetto currently serves as a Medical Science Liaison specializing in Diabetes and Obesity at Eli Lilly, where he leverages his extensive expertise in endocrinology and pediatrics to drive impactful healthcare solutions. With a Six Sigma Green Belt certification obtained in 2009, Gilberto is adept at applying process improvement methodologies to enhance operational efficiency within the pharmaceutical industry. His role involves closely monitoring the Human Growth Hormone (HGH) market across Italy, where he engages with approximately 40 thought leaders (TLs), primarily focusing on pediatricians and endocrinologists.
Gilberto's deep understanding of the pediatric diabetes landscape allows him to effectively communicate complex scientific information to healthcare professionals, ensuring that they are well-informed about the latest advancements and treatment options. His strategic approach to market access and product launch is instrumental in positioning Eli Lilly’s innovative therapies within a competitive healthcare environment.
In addition to his work in diabetes and obesity, Gilberto's diverse skill set encompasses oncology and osteoporosis, enabling him to contribute to cross-functional teams and broaden the scope of Eli Lilly's therapeutic offerings. His commitment to fostering collaborative relationships with healthcare providers not only enhances patient care but also drives the successful adoption of Eli Lilly’s products. Through his dedication and expertise, Gilberto Mossetto plays a pivotal role in advancing the treatment landscape for chronic conditions, ultimately improving patient outcomes in Italy and beyond.
